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Abstract
Background: 
The aim of this study was to measure the serum pepsinogen I 
and II levels in gastric cancer patients at a tertiary care centre 
in South India and to study the serum pepsinogen I/II ratio in 
patients with gastric cancer.
Methods:
 Thirty three patients: 17 with gastric cancer and 16 normal 
controls were studied. Serum levels of pepsinogen I (PG I) and 
pepsinogen II (PG II) were measured by ELISA.
Results: 
The mean PG I levels for cancer patients and controls were 
185.3 μg/l and 188.1 μg/l, respectively (P= not significant), the 
mean PG II levels were 21.2 μg/l and 12.7μg/l respectively (P= 
not significant).  The PG I/II ratio however was 12 in cancer and 
25 in controls: the ratio was significantly lower in cancer 
patients (P< 0.05).  
Conclusion: 
The serum pepsinogen I/II ratio is modified significantly in 
gastric cancer.
Introduction
Gastric cancer is a leading cause of cancer death in India. 
India was thought to have lower cancer rates than the Orient. 
However with the establishment of the National Cancer 
Registry, the actual disease load is being revealed.  Reports 
from the North Eastern parts of our country show very high 
rates of carcinoma stomach.  Results of treatment are often 
disappointing because most patients present late. Consumption 
of large amounts of red chillies, food at very high temperatures, 
smoked food containing nitrites, preserved food and alcohol 
consumption are the main risk factors for stomach cancer in 
India. Consumption of a tobacco extract 'Tuibur' has been 
linked to the high rates of Stomach cancer in Mizoram. More 
than 75% of cancers in India present in advanced stages.
The 5-year relative survival rates for stage I and stage II 
stomach cancers are about 77 percent and 48 percent 
respectively.  Stage IV tumours have very low survival rates 
around 4% for resectable and even lesser for unresectable 
tumours. Primary prevention or early detection is the best 
strategy for prevention and cure of stomach cancer.
Early diagnosis can improve the outcome of gastric cancer, as 
this disease is curable in the early stages. Screening for early 
detection of gastric precancerous changes may be helpful in 
diagnosis and treatment of cancer at curable stages. 
Various biomarkers of gastric cancer are under study. 
Pepsinogen I/Pepsinogen II as markers of atrophic gastritis in 
corpus, Gastrin-17 as marker of atrophic gastritis in antrum and 
anti H.Pylori antibodies are all under study in various 
populations.  A large body of work is available from Japan and 
China.
In 1975, Correa proposed the theory of a consecutive line of 
events leading to gastric cancer development: normal mucosa - 
chronic active gastritis - chronic atrophic gastritis - intestinal 
metaplasia - dysplasia - carcinoma in situ.  At present, this 
cascade of changes associates with a trigger role of H pylori 
and is called "Correa's gastric precancerous cascade.  A lot of 
recent research focuses on the role of H.Pylori infection and its 
role in the pathogenesis of cancer.  Chronic Helicobacter pylori 
(H pylori) infection is thought to be the trigger mechanism in 
60-90% of gastric cancer especially in the Orient.  Atrophic 
gastritis also alters the levels of the other enzymes of the 
stomach: pepsinogen and gastrin.  Pepsinogen I and the 
pepsinogen I/II ratio is being recommended as a screening test 
for gastric cancer especially in populations at high risk e.g. 
Japan and China. 
This study in our patients is to determine the serum persinogen 
I/II levels and to examine if there was any alteration in this ratio 
between patients with normal endoscopy and those with 
cancer.  
Pepsinogen: overview and clinical implications
Pepsinogen is a molecule which has been the focus of recent 
research in patients with gastric cancer. Human pepsinogens 
are proenzymes for the digestive enzyme pepsin originating in 
the gastric mucosa and are classified biochemically and 
immunochemically into two groups, pepsinogen I and 
pepsinogen II. These among other functions also act as growth 
factors and are protective for the gastric mucosa.
One group (Pg1-Pg5), called PGA or group I pepsinogen is 
characterized by electrophoretically faster migration and is 
found only in the fundus and body of the stomach. Group I 
pepsinogens are synthesized solely in the oxyntic glands and 
mucous neck cells of the gastric corpus. A protein precursor to 
pepsin, Pepsinogen I or Pepsinogen A is secreted exclusively 
by the chief cells of the gastric corpus. Serum pepsinogen 
levels reflect the morphologic and functional status of the 
stomach mucosa.  Lifestyle, genetic and infectious factors 
influence the serum levels of this enzyme.  This is also 
influenced by other malignancies and nonmalignant conditions. 
The levels of Pepsinogen I correlate directly with the active 
number of chief cells in this area. In cases of severe atrophic 
gastritis of the corpus region, the chief cells will be destroyed 
and the levels of Pepsinogen I will fall.  The majority of 
pepsinogens are secreted into the lumen of the stomach where 
they are metabolized into active pepsin. Small proportions 
about 1% of the pepsinogens diffuse into the blood circulation.
The second group (Pg6 and Pg7), termed pepsinogen C or 
group II pepsinogen, is localized in the whole stomach. It is also 
produced at sites distant from the gut, specifically, the 
pancreas, prostate, seminal vesicle, and lung. Pepsinogen C 
was also found to be a marker of breast cancers, with a more 
favorable response to hormone-based chemotherapy. This led 
to studies of the hormone responsiveness of a 1,438-base 
segment of the pepsinogen C promoter, which demonstrated a 
15-bp hormoneresponsive element that resembles the 
consensus sequence for glucocorticoid, androgen, and 
progesterone receptors. Synthesis of PGC has also been 
reported in numerous non-gastric tissues including the prostate 
gland and the Brunner's gland of the small intestine. The 
physiological significance of PGC in these tissues is not known 
and studies are limited by the lack of appropriate in vitro cell 
models. Animal models are under development. Serum 
concentration of PG II reflects the histological status of gastric 
mucosa. 
The ratio of concentration of PGI to PGII in serum of normal 
subjects is about 4:1. In case of atrophic corpus gastritis, the 
level of serum pepsinogen I decrease whereas the level of 
pepsinogen II remains stable or decreases slightly. The 
PGI/PGII ratio decreases linearly with increasing grade of 
atrophic gastritis in the corpus (2, 3). The ratio is < 2.5 when the 
atrophic gastritis is advanced (moderate or severe) in the 
gastric corpus. A combination of the serum pepsinogen I level 
and the pepsinogen I/II ratio has recently been recommended 
to screen for gastric cancer
Very few studies have been done in India. Serum pepsinogen 
(SP) levels were studied in 100 patients with gastroduodenal 
lesions, and 100 healthy volunteers. SP levels were 
significantly elevated in patients with duodenal ulcer (DU) and 
duodenitis compared to the controls. SP values above 150 ug 
Tyr/ml/24 hr were highly suggestive of duodenal ulcer disease. 
The mean values of SP in North India were found to be lower in 
both normal and DU subjects compared to the west.
Another study concluded that serum pepsinogen estimation is a 
useful diagnostic and screening tool in the diagnosis of 
carcinoma stomach.  This study showed that patients with 
carcinoma stomach had a significantly lower pepsinogen I level 
(87.2ug/L) and pepsinogen I/II ratio (4.3). The cut-off levels of 
pepsinogen I (115.3ug/L) and pepsinogen I/II ratio (6.2) when 
applied in parallel provided a sensitivity of 97% and a negative 
predictive value of 91.4%. 
Various cutoff values for screening have been proposed; 
typically, serum pepsinogen I less than 70μg/l and a PG I/II 
ratio of less than 3 are used for screening in other populations. 
The sensitivity and specificity ranged from 55% to 84.6% and 
73.5% to 78.9%. 
 The difference in the results in these populations can have 
various reasons. First, there is a difference in prevalence of 
gastric atrophy: this may be low in our population. Also, gastric 
atrophy is not always an essential intermediate step in gastric 
carcinogenesis. Different populations develop cancer due to a 
combination of factors. 
In the analysis by location, cancer found in both the proximal 
one third and the distal two thirds of the stomach showed a 
significant association with serum pepsinogen test levels; 
however, the magnitude of the association was stronger for 
body/distal cancer. Atrophic change in gastric mucosa spreads 
from the anal end to the oral end. Thus, the association 
between serum pepsinogen test levels and development of 
gastric cancer is considered stronger for distal cancer. This 
finding was in accord with those from previous case-control 
studies. 
With regard to depth of invasion, both early and advanced 
cancers were clearly associated with serum pepsinogen test 
levels. Some studies however did not detect early cancers.
Men have a higher risk of developing gastric cancer after 
severe gastric atrophy and serum pepsinogen levels mimic this. 
In animal experiments, this tolerance of women toward 
carcinogenesis has been explained in terms of their sex 
hormones. When the serum pepsinogen test is used to screen 
for gastric cancer, it might be preferable to vary the cutoff level 
according to sex. 
The lower incidence of gastric cancer among Indians as 
compared to Chinese cannot be explained by differences in H. 
pylori or serum PG. Other modifying factors such as genetic 
factors may be important.
Genetics of pepsinogen
The absence of detectable immunologic crossreactivity 
between the pepsinogens A and C results from divergent 
evolution of sequences located on the surface of the zymogens 
in contrast to the strongly conserved active site regions located 
within the binding cleft of the enzymes, inaccessible for 
antigenic recognition. Although antigenically distinct, 
pepsinogens A and C exhibit a high degree of homology in their 
active site regions. Hayano et.al. isolated the entire human 
pepsinogen C gene from a cosmid genomic library. Pepsinogen 
genes comprise nine exons and may be multiple, especially for 
pepsinogen A. The latter and progastricsin predominate in adult 
animals, while pepsinogen F and prochymosin are the main 
forms in the fetus/infant. 
The switching of gene expression from fetal/infant to adult-type 
pepsinogens during postnatal development is noteworthy, being 
regulated by several factors, including steroid hormones. 
Pepsinogen C is a type 2 cell-specific marker that exhibits tight 
developmental regulation in vivo during human lung 
development, as well as during in vitro differentiation and 
dedifferentiation of type 2 cells.
PGA is the precursor of pepsin A. PGC, also known as 
progastricsin, is the precursor of pepsin C or gastricsin. PGA 
has five electrophoretic isozymogens (Pg 1-5). PGA is 
remarkably heterogeneous as shown by an extensive protein 
electrophoretic polymorphism resulting in multiple haplotypes 
containing different combinations of the individual PGA genes 
and one or more post-translational modifications of the primary 
gene products. Two principal forms of PGA polymorphism have 
been recognised: phenotype A, which possesses all five PGA 
isozymogens; and phenotype B, which lacks Pg 5.
The PGC gene was localized to human chromosome 6p21.1-
pter by analysis of mouse x human somatic cell hybrids. PGC 
has two electrophoretic isozymogens (Pg 6 and Pg 7). No 
genetic variation has been described at the protein level. 
However at the DNA level, a 100 bp insertion-deletion RFLP 
located between exons 7 and 8 was observed with several 
restriction enzymes. The RFLP for PGC was identified in 
Indian, Caucasians and Japanese. Whether this polymorphism 
could affect the expression of PGC gene or regulate the PGC 
gene expression when the stomach was attacked by some 
pathogenetic factors is not known. Another possible explanation 
of the association between the PGC gene polymorphism and 
gastric cancer was that the PGC gene was not itself 
responsible for the predisposition but one of the responsible 
genes was closely linked to it. 
PCG gene polymorphisms have also been shown to be 
associated with gastric body cancers and this is another 
exciting new field of research. There is a significant association 
between genetic polymorphisms at the PGC gene locus and 
gastric ulcer disease and that there is genetic heterogeneity in 
this disease; this depends on the location of the gastric ulcer. 
The PGA: PGC ratio was significantly lower in patients with 
gastric body ulcer than in patients with duodenal ulcer and in 
patients with angular or antral ulcer. Ulcers may be more 
proximal when atrophic gastritis is more severe. These findings 
suggest that the different pathophysiological factors between 
gastric body ulcer and gastric angular or antral ulcer may have 
underlying genetic differences. 
This is a field open for future research and identification of gene 
mutations predisposing to cancer may be used as diagnostic 
tools.
Biochemistry of pepsinogens
Five types of zymogens of pepsins, gastric digestive 
proteinases, are known: pepsinogens A, B, and F, 
progastricsin, and prochymosin. The amino acid and/or 
nucleotide sequences of more than 50 pepsinogens other than 
pepsinogen B have been determined to date. Phylogenetic 
analyses based on these sequences indicate that progastricsin 
diverged first followed by prochymosin, and that pepsinogens A 
and F are most closely related. Tertiary structures, clarified by 
X-ray crystallography, are commonly bilobal with a large active-
site cleft between the lobes. Two aspartates in the center of the 
cleft, Asp32 and Asp215, function as catalytic residues, and 
thus pepsinogens are classified as aspartic proteinases. 
Conversion of pepsinogens to pepsins proceeds 
autocatalytically at acidic pH by two different pathways, a one-
step pathway to release the intact activation segment directly, 
and a stepwise pathway through a pseudopepsin(s). The 
active-site cleft is large enough to accommodate at least seven 
residues of a substrate, thus forming S4 through S3' subsites. 
Hydrophobic and aromatic amino acids are preferred at the P1 
and P1' positions. Interactions at additional subsites are 
important in some cases, for example with cleavage of 3-casein 
by chymosin. Two potent naturally occurring inhibitors are 
known: pepstatin, a pentapeptide from Streptomyces, and a 
unique proteinous inhibitor from Ascaris.
Gastrin
Another molecule which can be targetted as a diagnostic test is 
gastrin.  Gastrin is synthesized in G-cells, which are found in 
the gastric antrum. The gastrin secreted by the antrum is over 
90% of type G-17 whereas the gastrin secreted by the 
duodenum is primarily type G-34. The fasting serum gastrin is 
primarily in the form of G-34 but the proportion of type G-17 
increases after the dietary stimulus. The secretion of gastrin-17 
can be studied with a simple protein stimulation test. First, a 
blood sample is taken after fasting, after which the patient eats 
a protein-rich meal. The maximum increase in the level of 
gastrin-17 can be seen in the serum within 20 min. If the serum 
gastrin does not increase as a result of protein or other 
physiological stimulation it is an indication of the loss of gastrin 
secreting G cells, i.e., an indication of the atrophy of the antrum 
mucosa. It is possible to make indirect conclusions of the status 
of the antrum mucosa by simultaneously assaying the serum 
gastrin and acid output. In the cases with atrophic antral 
gastritis and loss of antral G cells, serum gastrin remains low 
although the stomach is achlorhydric or hypochlorhydric. 
 H. pylori eradication may cure gastritis and help to prevent 
further progression of gland loss and reduce the risk for gastric 
cancer in populations where its correlation with cancer is high. 
Screening and treatment of H. pylori infection might in theory be 
cost-effective for the prevention of gastric cancer in such 
populations.  
          Patients and methods 
This study was a case control study done on a population of 
hospital based patients at a tertiary care centre in South India. 
Specimens and data were collected prospectively from 
December 2006 to December 2007.
Forty three patients were diagnosed to have carcinoma 
stomach in the period December 2006 to December 2007.
Seventeen of them were chosen randomly as study cases.  The 
control group comprised of an equal number of patients. 
Control subjects were selected from among those who had no 
endoscopic abnormalities on evaluation for dyspepsia.
Patients were interviewed with a questionnaire; data recorded 
in proformas and blood samples were collected for assay. 
Inclusion criteria were patients with malignant gasric ulcers on 
endoscopy.
Exclusion criteria were patients with previous gastric surgery or 
any other treatment for stomach cancer, such as chemotherapy 
or radiotherapy.  
Informed consent was obtained from all patients before the data 
was collected.
Serum pepsinogens were measured by using pepsinogen I and 
II Biohit kit. This is manufactured by the Biohit Diagnostics and 
is commercially available.  
Methods
Sample collection
Patients were fasting for 10 hours before blood sampling. Blood 
sample was collected by venipuncture into a plastic EDTA tube 
without additives. Plasma blood tubes were mixed immediately 
by turning them upside down 5-6 times and tubes for serum 
allowed to clot (for minimum 30 minutes) at room temperature 
(20...25°C). Serum after clotting was separated by 
centrifugation and stored frozen_20°C. Samples were mixed 
thoroughly after thawing. Grossly hemolysed, lipemic or turbid 
specimens were avoided and samples were not repeatedly 
froze and thawed.
Working principle of the ELISA
The pepsinogen kit is a microplate-based quantitative enzyme 
linked immunosorbent assay (ELISA) for the determination of 
human pepsinogen from plasma or serum samples. This ELISA 
is based on a sandwich enzyme immunoassay technique with a 
PG specific capture antibody adsorbed on a microplate and a 
detection antibody labeled with horseradish peroxidase(HRP). 
The assay proceeds according to the following reactions:
1. A monoclonal antibody, specific to human PG, on the 
polystyrene surface of the wells binds PG molecules present in 
the sample.
2. Wells are washed to remove the residual sample.
3. An HRP-conjugated monoclonal detection antibody is added 
to the wells and it binds to the PGI molecules.
4. The wells are washed and TMB-substrate is added. The 
substrate is oxygenized by the enzyme and a blue colored end 
product is produced. 
5. The enzyme reaction is terminated with stop solution. The 
solution in the microwells should turn yellow. The intensity of 
the yellowish color developed is directly related to the PG 
concentration of the sample.
Details of the Kit:
The reagents are sufficient for 96 wells and three separate 
runs. 
1. Microplate
Contents: 12 x 8 strips in frame coated with high-affinity, 
monoclonal anti-human -PGI IgG1.
2. Washing Buffer Concentrate (x 10)
Contents: 120 ml of 10 x phosphate buffer saline (PBS) 
concentrate containing Tween 20 and 0.04% ProClin 300 as 
preservative.
Preparation: Dilute 1 to 10 (e.g. 100 ml+ 900 ml) with distilled 
water and mix well.
Stability: The diluted solution is stable for two weeks 
refrigerated (2…8 °C).
3. Diluent Buffer 
Contents: 100 ml of phosphate buffer containing bovine serum 
albumin, Tween 20, 0.04% ProClin 300 as preservative and red 
dye extract.
4. Blank Solution
Contents: One vial containing 1.5 ml of human serum-based 
phosphate buffer with 0.1% ProClin 300 as preservative.
5. Calibrators
Contents: Three vials each containing 1.5 ml of human serum-
based calibrators with 0.1% ProClin 300 as preservative. 
6. Control
Contents: One vial containing 1.5 ml of human serum-based 
PGI control with 0.1% ProClin 300 as preservative. 
6.7. Conjugate Solution
Contents: 15 ml of HRP-conjugated monoclonal anti-human-
PGI in stabilizing buffer with 0.02% methylisothiazolone, 0.02% 
bromonitrodioxne and 0.002% other active isothiazolones as 
preservatives.
8. Substrate Solution
Contents: 15 ml of tetramethylbenzidine (TMB) in aqueous 
solution.
9. Stop Solution
Contents: 15 ml of 0.1 mol/l sulphuric acid. 
10. Incubation Covers 
11.Other materials
1.  Distilled or deionized water
2.  Micropipettes and disposable tips
3.  Pipettes to accurately deliver 1 - 10 ml
4.  8-channel pipette delivering 100 μl
5.  Graduated cylinder, 1000 ml
6.  Vortex mixer for sample dilutions
7.  Test tubes for specimen dilutions
8.  Microplate washer
9.    Paper towels or absorbent paper
10.  Incubator, 37°C
11.  Microplate reader, 450 nm
Storage and transport
The Pepsinogen kit was stored and transported refrigerated 
(2…8°C) till use. Liquid components were clear. The substrate 
solution was pale red. (Any other color indicates deterioration of 
the substrate solution.)
Test procedure
Preliminary preparations
Allow all reagents and the microplate to reach room 
temperature (20…25°C). Warm the incubator to 37°C. Dilute 
the washing buffer concentrate 1 to 10 (e.g. 100 ml + 900 ml) 
with distilled or deionized water. 
Specimen dilution
Dilute serum or plasma samples 1 to 10 (50 μl + 450 μl) with 
the diluent buffer, mix well.
STEP I 
Mix and pipette 100 μl of the blank solution (BS), the calibrators 
(CAL1-CAL3), the control and diluted samples (S1, S2 etc.) into 
the wells as duplicates (see Figure 1). Cover the plate with the 
incubation cover. Incubate for 60 minutes at 37°C.
WASHING
Wash the wells three times with 350 μl of the diluted (1 to 10) 
washing buffer and gently tap the inverted plate a few times on 
a clean paper towel.
STEP II
Pipette 100 μl of the mixed conjugate solution into the wells, 
preferably with an 8-channel pipette. Cover the plate with the 
incubation cover. Incubate for 30 minutes at 37°C.
WASHING
Wash the wells three times with 350 μl of the diluted (1 to 10) 
washing buffer and gently tap the inverted plate a few times on 
a clean paper towel.
STEP III
Pipette 100 μl of the mixed substrate solution into wells with an 
8-channel pipette. Start the incubation time after pipetting the 
substrate solution into the first strip and continue the incubation 
for 30 minutes at room temperature (20…25°C). Avoid direct 
exposure to light during incubation.
STEP IV
Pipette 100 μl of the mixed stop solution with an 8-channel 
pipette into the wells.
MEASURING
Measure the absorbance at 450 nm within 30 minutes.
 A low P/S-PGI result (P/S-PGI<25 μg/l) indicates advanced 
atrophic gastritis of the corpus mucosa. This cut-off level has 
been determined using the Biohit Pepsinogen I ELISA kit based 
on large clinical material. 
The test kit 
Microplates at analysis
Results and analysis
Forty three patients were diagnosed to have carcinoma 
stomach in the period December 2006 to December 2007.
There were 34 male and 9 female patients.  
Table 1: Age and sex distribution of patients from Dec 06-07 
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Seventeen of them were chosen randomly as cases: there were 
no similar Indian studies at the time the study commenced: 
sample size was indirectly calculated based on the available 
Indian studies.
Seventeen patients with gastric cancer (mean age 58.3 years; 
range, 31-74 years) and 17 age matched control subjects were 
studied. There were 15 male and 2 female cancer patients- the 
male:female ratio was 7.5:1.  
Table 2: Male: female distribution of study patients
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Table 3: Resectability at diagnosis in study patients
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Seven out of 15 tumours were unresectable at diagnosis. 
There were 6 poorly differentiated and 10 moderately 
differentiated tumours.  Tissue sample was not adequate for 
grading in one patient.
Of the unresectable tumours, only 2 were poorly differentiated: 
majority was moderately differentiated (5/7). 
Table 4: Tumour histology in study patients
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Three patients (2male, 1 female) with operable tumours did not 
undergo any further treatment at this centre after diagnosis. 
Seven patients underwent resection. Four underwent subtotal 
gastrectomy and 3 underwent distal gastrectomy. 
Four patients were followed up and of these three were well at 
7 months.  Two had undergone subtotal and one distal 
resection with tumour free margins on histology: they had 
moderately differentiated adenocarcinoma. One patient had 
evidence of nodal recurrence within a month and he had a 
poorly differentiated tumour.  
Intestinal metaplasia and gastric atrophy was not reported in 
any of the study patients.
Serum levels of pepsinogen I, pepsinogen II, and the PG I/II 
ratio in the cancer patients and controls is depicted in the 
following tables. 
Table 5: Levels of Pepsinogen I, II and the I/II ratio in cancer 
patients
Patients 
Pepsinogen 
I ug/l
Pepsinogen 
II ug/l
Pepsinogen 
I/II ratio
1. 232.4 23 10.11
2. 216.9 12.2 17.7
3. 188.7 22.9 8.2
4. 234.6 14 16.7
5. 224.6 24.6 9.1
6. 146.1 17.6 8.3
7. 100 22.8 4.3
8. 196.3 63.4 3.1
9. 66.6 20.2 3.2
10. 225.6 18.2 12.3
11. 121.1 5.7 21.2
12. 233.8 9.3 25.1
13. 59.7 5.9 10.1
14. 228.8 32.5 7.04
15. 227.4 8.7 26.1
16. 212 11.8 17.9
17. 234.9 47.7 4.9
Table 6: Levels of Pepsinogen I, II and the I/II ratio in controls
Controls 
Pepsinogen 
I
Pepsinogen 
II
Pepsinogen 
I/II ratio
1. 210.7 12.5 16.8
2. 171.1 9.6 17.8
3. 215.3 17.3 12.4
4. 80.7 2.6 31
5. 167.1 6.2 26.9
6. 231.3 30.5 7.5
7. 203.8 13.7 14.8
8. 139.9 2.3 60.8
9. 191.9 9 21.3
1
0
. 227.7 9.8 23.2
11. 229 15.1 15.16
12. 161.6 7.9 20.4
13. 182.7 4.9 37.2
14. 134.6 4.8 28
15. 235.1 22.3 10.5
16.            226.4              35.4             63.9
17.               234             17.8             13.1
Statistical analysis
These results showed serum pepsinogen I values that were 
very high in comparison to the values in other populations.  
The statistical test used was the significance of the normal 
deviate and the standard error of deviation of two means.
There was no satistically significant difference in the levels of 
PepsinogenI or II when tested individually.  However, the 
Pepsinogen I/II ratio was significantly different between the two 
groups. 
The normal serum I/II ratio is thought to be around 4:1 and this 
falls to below 2.5:1 in patients with gastric atrophy and cancer. 
The average levels of Pepsinogen I is between 50-150ug/l and 
Pepsinogen II around 15 –20ug/l. In our paients the 
corresponding levels were 185ug/l and 21ug/l respectively: 
these values were much higher than what has been reported in 
literature.  The average pepsinogen I/II ratio was 12 in patients 
and 25 in controls which is much higher than what is reported in 
other populations..
Using a cutoff value of 7 for the pepsinogen I/II ratio and 
applying the test  yields a sensitivity of around 47% but 
specificity of 100%.  The positive predictive value of the test at 
this cutoff is 100%.  Other Indian reports have also 
recommended similar cutoff values.
The other clinical or pathological variables had no effect on 
serum pepsinogen levels. 
Discussion
Gastric cancer is the second most common cancer in the world. 
The mortality of gastric cancer is still in the leading status of all 
cancers. The 5-year survival rate of gastric cancer is low, and 
identification and a better control of risk factors seem to be the 
most effective means of prevention.
Screening for early detection of gastric precancerous changes 
may be helpful in diagnosis and treatment of cancer at curable 
stages.
 Many factors ascribe to the cause of gastric cancer, including 
the living habit, nutrition, microbe, and genetic predisposition. 
Recently, following the primary completion of Human Genome 
Project, the association of genetic polymorphisms with diseases 
came to the study frontier. Genetic polymorphisms are defined 
as variations in DNA that are observed in 1 % or more of the 
population. The study of genetic polymorphisms promises to 
help define pathophysiologic mechanisms, to identify 
individuals at risk for disease and to suggest novel targets for 
drug design and treatment. Family members of gastric cancer 
patients have been found to have a 1.5-fold to 3-fold increase in 
the risk of developing this cancer. This familial aggregation may 
be due to genetic or environmental factors shared by family 
members.   
H.pylori is considered a WHO class I carcinogen. Chronic 
H. pylori gastritis, in more than half of the affected subjects, 
could lead to a gradual loss of glandular structures with its 
specialized cells and a collapse of the reticulin skeleton of the 
mucosa, a condition of atrophic gastritis. As a result, the 
glandular layer of the mucosa became thinner, and glands were 
replaced by fibrosis and intestinal metaplasia. The major clinical 
importance of this condition was that it could significantly 
increase the risk for the intestinal type of gastric cancer. This 
risk might be elevated up to 90- fold in subjects with severe 
atrophic gastritis throughout the complete stomach. The annual 
incidence of gastric cancer among patients with atrophic 
gastritis varied in cohort studies between 0.3 and 1.0%. This 
could explain the interest in the diagnosis of atrophic gastritis. 
At present, there is a wide circle of questions related to the 
diagnosis of critical stages of gastric carcinogenesis - gastric 
epithelial atrophy, intestinal metaplasia and dysplasia. 
Therefore, it is extremely important to recognize dyspeptic 
patients who have very high risk of gastric malignant changes 
and require dynamic surveillance with the purpose of early 
revealing of the preneoplastic changes in stomach mucosa. 
Atrophic gastritis is a serious disease, which often does not 
receive much attention. The relationship between gastritis, 
atrophic gastritis and other diseases of the stomach is based on 
the fact that infection and atrophy could alter the physiological 
functions of the stomach and influence the growth and growth 
control of epithelial cells in the stomach. These consequences 
varied depending on whether the changes of the gastric 
mucosa caused by gastritis were located in the antrum or the 
corpus or both. 
H. pylori infection is known to be associated with a raised 
serum pepsinogen II level and a decreased PG I/II ratio. 
Expression of cytotoxin-associated gene A (cagA) which is 
known to be associated with more active mucosal inflammation 
and, hence, higher levels of serum pepsinogen I and II than 
other strains.   However the incidence of cancer is the same in 
cagA positive and negative patients.
However not all cancers are associated with atrophic gastritis.
The most accurate diagnostic method of gastrointestinal tract 
diseases is endoscopy with subsequent biopsy, which should 
be made in all patients with the presence of clinical symptoms. 
However, because of patchy characteristics of atrophic 
changes in stomach mucosa, some histological researches 
could give false - negative results. Due to invasiveness of 
biopsy, it is expedient to make only for monitoring precancerous 
changes in stomach mucosa. 
For the selection of patients recommended to biopsy, the 
presence of a screening method is necessary. Ohata et al. 
assessed H. pylori–negative subjects and found an increased 
risk of gastric cancer for those with a positive pepsinogen test 
level (pepsinogen I 70 ng/ml and pepsinogen I/II ratio 3.0) 
compared with subjects with a negative level. It is reasonable 
that pepsinogen test positivity, a marker of chronic atrophic 
gastritis, is closely associated with this type of gastric cancer. 
On the other hand, diffuse-type gastric cancer is thought to be 
genetically determined, at least in part, and to be less 
associated with environmental factors. This type of cancer does 
not progress through severe atrophic gastritis; hence, no clear 
association with the serum pepsinogen test is seen. 
In our study, the baseline levels of Pepsinogen as well as the 
cutoff for PG I/II ratio was significantly higher.  This might be 
explained by a low incidence of atrophic gastritis in our 
population.  Other etiopathologies assume greater significance 
in this setting.
Noninvasive detection of gastric mucosal atrophy by means of 
enzyme immunoassay with assessment of G-17 and PG1 
levels can be offered as the screening tool for gastric 
precancerous conditions. On the other hand, this method does 
not diagnose intestinal metaplasia and cancer development in 
stomach mucosa. Therefore, the results of serological 
screening indicating the stomach mucosal atrophy require 
carrying out the chromoendoscopy with subsequent mucosal 
biopsy, for revealing probable progressing of atrophic process 
with development of intestinal metaplasia, dysplasia or gastric 
cancer. 
Cost of screening and the ethical implications of screening also 
have to be considered carefully in a developing country like 
India.
This study is limited by the number of patients studied: larger 
studies are needed before this test becomes clinically 
applicable.
Conclusion
Favourable patient outcome in the management of carcinoma 
stomach still depends on early detection. At present endoscopy 
is the gold standard of diagnosis.  Screening tools are under 
development but there is no current test which can replace 
endoscopy.  These also have to take into account the different 
nature of the disease in Indian patients as well as cost.  
Our study evaluates a test which has been recommended as a 
alternative or adjunct to the diagnosis of gastric cancer.  We 
find a significant difference in test results in cancer patients.
In future further subset analysis by location of cancer, enzyme 
levels between different communities, temporal change of 
enzyme levels with progression of disease also needs to be 
studied. Studies with larger numbers of patients are needed for 
validation of this test before routine clinical use.
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Appendix
Study proforma for cases
  
Form no.
Name                                  Hospital 
number    :
Age     :                                              Address 
Sex     :                                                                     Telephone 
number:
Date of detection:
Risk factors (circle if present)
1. Smoking
2. Alcohol
3. Documented H. pylori
4. Previous gastric surgery (if yes, details and date)
5. Pernicious anemia
6. Menetriers disease
7. Blood group A
8. Family history
      9.   Diet - Smoked fish / spices / tea
Socio economic status:                          :   Poor / not poor
Known past history of ulcer disease:   Yes      ___years / No
Comorbidity
Details of family history 
          Family tree 
Symptoms      
                                                                
Clinical examination
Pre op investigations:
Blood                          Hb :
Symptoms yes no
Weight loss
abdominal pain
Anorexia
Vomiting
Dysphagia
Haematemesis
Malena
Non specific 
dyspepsia
  Finding ye
s
no
Palpable abdominal 
mass
Jaundice
Ascites
SCLN
Rectal deposits
Endoscopy:
Distance in 
Cm
GE junction at   
Growth extending 
from 
  
Growth extending to
Pylorus
Duodenum
Radiological investigations:
Biopsy (endoscopic)
Surgery done    :
Operative findings   :                                        
        Primary tumour
        Regional nodes
        Distant metastasis     
        
Bormann type   : 1/ 2 / 3 / 4               Laurens type      : 
Intestinal / Diffuse
Post op biopsy    :
         Histology             : Well / moderately / poorly 
differentiated adenocarcinoma
         Sub type              : Papillary / tubular / mucinous / signet 
cell /others
         Margins               : Proximal   - 
                                        Distal         -
         Nodes                  :
         Size of tumor      :
TNM stage        :
AJCC stage       :
Study proforma for controls
Form no.
Name                                  Hospital 
number    :
Age     :                                                    Address 
Sex     :                                                                     Telephone 
number:
Date of detection:
Risk factors (circle if present)
1. Smoking
2. Alcohol
3. Documented H. pylori
4. Previous gastric surgery (if yes, details and date)
5. Pernicious anemia
6. Menetriers disease
7. Blood group A
8. Family history
9. Diet - Smoked fish / spices / tea
Socio economic status:                          :   Poor / not poor
Known past history of ulcer disease:   Yes      ___years / No
Comorbidity
Details of family history 
Symptoms                                           Clinical examination
                                                             
Pre op investigations:
Blood                          Hb :
Endoscopy:
Distance in 
Cm
GE junction at   
Growth extending   
          Family tree 
Symptoms yes no
Weight loss
abdominal pain
Anorexia
Vomiting
Dysphagia
Haematemesis
Malena
Non specific dyspepsia
  Finding yes no
Palpable abdominal mass
Jaundice
Ascites
SCLN
Rectal deposits
from 
Growth extending to
Pylorus
Duodenum
Radiological investigations:
Biopsy (endoscopic)
                              Informed consent form   
Title of the study   :  Levels of serum pepsinogen I and II in patients 
with  carcinoma  stomach  and  the  genetic  polymorphisms  of 
pepsinogen  C  associated  with  carcinoma  stomach  in  the  Indian 
population.
 Institution             : Christian Medical College
 Nature and purpose of the study: you are taking part in 
studies that will asses the level of a particular enzyme in your 
blood.  This enzyme is altered in many diseases affecting the 
stomach.  Indian patients may have different enzyme patterns. 
However this has so far not been studied in India. Your blood 
enzyme will be studied and compared to other patients to see if 
there is any significant difference.
You will have to give 8 ml blood sample after undergoing your 
gastroscopy. There is no appreciable risk of giving this small 
blood sample. The records from this study will remain strictly 
confidential at all times. It will be available only to the doctors 
and researchers conducting the study. You can refuse to be a 
part of this study and this will not affect your future medical care 
in any way.
Consent:             
I have read /had read out to me the above information and give 
informed consent after understanding it.
Signature of the patient:  
Signature of the witness:
Patient name         :
Hospital number   :
Consent form no. :
